Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06206564 · ClinicalTrials.gov registry record · Phase 2
Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants
A Phase 2 study of Anal High-grade Squamous Intraepithelial Lesion and Anal HSIL, sponsored by Frantz Viral Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 2
- Study locations
NCT06206564: Recruiting Phase 2 study of Anal High-grade Squamous Intraepithelial Lesion and Anal HSIL, sponsored by Frantz Viral Therapeutics.
NCT06206564 is a Phase 2 study of Anal High-grade Squamous Intraepithelial Lesion and Anal HSIL that is actively recruiting participants, run by Frantz Viral Therapeutics. The registered enrollment target is 48 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06206564, a Phase 2 study of Anal High-grade Squamous Intraepithelial Lesion and Anal HSIL, is actively recruiting participants, sponsored by Frantz Viral Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a phase II double blind, placebo-controlled, randomized study of artesunate ointment for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)
Primary Outcome
Number of participants with complete and partial response after four 5-day cycles of artesunate ointment
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Artesunate ointment
Study Locations (2)
Illinois
- Anal Dysplasia Clinic MidWest - Chicago
New York
- Laser Surgery Care - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2024-01-12 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What NCT06206564 shows while recruiting
NCT06206564 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% lower).
The record links to 4 conditions, with Anal High-grade Squamous Intraepithelial Lesion appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06206564 reports a single indexed study location in Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT06206564 about?
NCT06206564 is a clinical study titled "Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants". This is a phase II double blind, placebo-controlled, randomized study of artesunate ointment for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)
What is the current status of trial NCT06206564?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2024-01-12. Estimated completion is 2026-12-31.
What conditions does trial NCT06206564 study?
This clinical trial studies the following conditions: Anal High-grade Squamous Intraepithelial Lesion, Anal HSIL, Anal HPV Infection, AIN.
What interventions are being tested in trial NCT06206564?
The interventions under investigation include: Placebo (DRUG), Artesunate ointment (DRUG).
Who is sponsoring clinical trial NCT06206564?
This trial is sponsored by Frantz Viral Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06206564 being conducted?
This trial has 2 study locations across Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anal High-grade Squamous Intraepithelial Lesion
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06206564's enrollment target sits among peer trials
48 1265th of 2000 higher than 719 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI